Lipedema in Focus: Scientific and Clinical Updates from Boston

Lympha Press at the 2026 Boston Lymphatic Symposium

February 19–20, 2026 | Boston, Massachusetts

On February 19–20, 2026, Lympha Press participated in the Boston Lymphatic Symposium, an internationally recognized scientific meeting dedicated this year to lipedema, diagnostic refinement, and the evolving understanding of lymphatic disease.

Hosted by the Boston Lymphatic Center — a joint program of Beth Israel Deaconess Medical Center and Boston Children's Hospital — in partnership with Lymphatic Education & Research Network, the symposium has become a leading forum for advancing research in lipedema, lymphedema, and lymphatic disorders since its launch in 2016.

Representing Lympha Press and its global manufacturer, Mego Afek, were Barak Hofer, CEO, and Deborah Gross, Director of Worldwide Clinical Marketing.

Scientific Focus: Lipedema Pathophysiology and Diagnostic Criteria

The 2026 program concentrated on improving diagnostic clarity in lipedema and distinguishing it from primary lymphedema and obesity-related adiposity.

Molecular and Cellular Mechanisms in Lipedema

Dr. Sara Al-Ghadban, PhD, an expert in adipose tissue biology, presented research on adipose-derived stem cells as potential drivers of lipedema syndrome. Her data emphasized the interaction between inflammation pathways and estrogen-responsive signaling, contributing to a more precise model of lipedema pathophysiology.

Lipedema vs. Primary Lymphatic Disease

Dr. Robert Damstra, MD, PhD, internationally recognized for his work in lymphology and lymphedema management, reviewed Dutch diagnostic criteria for lymphedema and articulated the position that lipedema should not be classified as a primary lymphatic disease. His presentation reinforced the importance of accurate differential diagnosis in lymphatic medicine.

Lipedema-Associated Pain and Hyperalgesia

Dr. Joseph Rutkowski, PhD, and Dr. Tim Hucho, PhD, presented mechanistic insights into lipedema-related pain, including hyperalgesia responses and the development of lipedema-specific pain assessment tools. Their work strengthens the neurological dimension of lipedema research and supports more targeted clinical evaluation.

Obesity, Metabolism, and the 2020 European Consensus

Dr. Tobias Bertsch, MD, a contributor to the 2020 European consensus on lipedema, addressed the role of obesity and metabolic dysfunction in lipedema. His session emphasized the paradigm shift recognizing lipedema as a distinct clinical entity with inflammatory and metabolic components.

Multimodal Therapy and Tissue Sodium as a Biomarker

Dr. Paula Donahue, MD, vascular and lymphatic specialist, presented findings on multimodal manual therapy and demonstrated measurable reductions in tissue sodium levels following treatment. Tissue sodium was discussed as a potential biomarker for inflammation modulation in lipedema management.

Emerging Therapies: GLP-1 Agonists, Weight Reduction, and Metabolic Remodeling

Several sessions examined dietary strategies, GLP-1 agonists, metabolic regulation, and weight reduction in patients with lipedema and obesity. Discussions focused on mechanisms of action, systemic inflammation, adipose remodeling, and the psychosocial burden of chronic lymphatic disease.

A parallel patient symposium strengthened the clinical program by integrating lived experience into evidence-based dialogue, highlighting the importance of multidisciplinary collaboration in lipedema.

Relevance to Pneumatic Compression Therapy and Lymphatic Management

As a global leader in pneumatic compression therapy for lymphedema and lipedema, Lympha Press remains committed to aligning innovation with evolving clinical research.

Key themes emerging from the 2026 Boston Lymphatic Symposium directly impact compression therapy practice:

• Improved diagnostic precision in lipedema and lymphedema
• Greater understanding of inflammatory and metabolic pathways
• Integration of pain mechanisms into treatment planning
• Multidisciplinary management models for lymphatic disease

Ongoing participation in high-level scientific forums reinforces Lympha Press’s commitment to evidence-based practice and advancing patient outcomes worldwide.